These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22011886)

  • 1. Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism.
    Yamamoto M; Ogata H; Mizobuchi M; Yoshida N; Kumata-Maeta C; Koiwa F; Shishido K; Kinugasa E
    Clin Exp Nephrol; 2012 Apr; 16(2):292-9. PubMed ID: 22011886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.
    Frazão JM; Messa P; Mellotte GJ; Geiger H; Hagen EC; Quarles LD; Kerr PG; Baños A; Dehmel B; Urena P
    Clin Nephrol; 2011 Sep; 76(3):233-43. PubMed ID: 21888861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
    Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
    Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diameter of parathyroid glands measured by computed tomography as a predictive indicator for response to cinacalcet in dialysis patients with secondary hyperparathyroidism.
    Hong YA; Cho YS; Kim SW; Jung MY; Lee EA; Ko GJ; Pyo HJ; Hwang SY; Suh S; Kwon YJ
    Kidney Blood Press Res; 2015; 40(3):277-87. PubMed ID: 26022985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid decrease of intact parathyroid hormone could be a predictor of better response to cinacalcet in hemodialysis patients.
    Kim JK; Kwon YJ; Kim SW; Kim YH; Park CW; Choi KB; Hwang SD; Choi KH
    Yonsei Med J; 2013 Mar; 54(2):453-63. PubMed ID: 23364981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)].
    Reichel H; Braun J
    Dtsch Med Wochenschr; 2011 Jan; 136(4):123-8. PubMed ID: 21181622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism?
    Kakuta T; Tanaka R; Kanai G; Sawaya A; Hirukawa T; Sato A; Saito A
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S20-7. PubMed ID: 19765255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
    Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
    Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy.
    Lomonte C; Antonelli M; Losurdo N; Marchio G; Giammaria B; Basile C
    Nephrol Dial Transplant; 2007 Jul; 22(7):2056-62. PubMed ID: 17449495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.
    Charytan C; Coburn JW; Chonchol M; Herman J; Lien YH; Liu W; Klassen PS; McCary LC; Pichette V
    Am J Kidney Dis; 2005 Jul; 46(1):58-67. PubMed ID: 15983958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of clinical-ultrasonographic feature model to predict the severity of secondary hyperparathyroidism.
    Zhang X; Xu W; Huang T; Huang J; Zhang C; Zhang Y; Xie X; Xu M
    Ren Fail; 2022 Dec; 44(1):146-154. PubMed ID: 35164637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
    Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
    Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
    Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
    Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
    Mercadal Orfila G; Blasco Mascaró I
    Farm Hosp; 2012; 36(1):11-5. PubMed ID: 21514862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
    Sharma A; Marshall TS; Khan SS; Johns B
    Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
    Bucharles SGE; Barreto FC; Riella MC
    J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The assessment of cynacalcet (Mimpara) accompanied by alfacalcidol treatment efficacy in haemodialysis patients with different secondary hyperparathyroidism severity recognized by iPTH].
    Zwiech R; Dryja P; Łacina D; Nykiel P; Sek-Szczepanowska K; Bratkowska K; Pietrzak B; Chrul S
    Wiad Lek; 2011; 64(4):267-73. PubMed ID: 22533150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism.
    Meola M; Petrucci I; Barsotti G
    Nephrol Dial Transplant; 2009 Mar; 24(3):982-9. PubMed ID: 19181759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.